Top of this page
Skip navigation, go straight to the content

Investors Overview

we aspire to be the patient-preferred biotech leader. 

To achieve this goal, UCB has become an innovation-driven global biopharmaceutical company creating value for patients, the company, its shareholders and society in general.

Our work has an impact on the lives of many people. Every UCB employee is committed to follow the strict regulatory standards for research, development, manufacturing and distribution of our products to ensure we meet all safety, quality, regulatory, legal and environmental requirements.

In an ever-changing and more complex environment, UCB’s patient value strategy is the best route to achieve this ambition and long-term success. 

2019 integrated report

Business general picture


IR events

DateEvent details
03 March
Credit Suisse 2020 Healthcare One-on-One conference, London1/1 meetings
04 March
Credit Suisse 2020 Healthcare One-on-One conference, London1/1 meetings
10 March
Roadshow in ParisIf you are interested in meeting UCB, please contact Bank of America Merrill LYnch
24 March
J.P. Morgan 5th Global ESG Conference, ParisUgiam ipsum del ullaorpero dolores sit amet dion ulluptat dolor suscillu

Agreement to acquire
Ra Pharma

image description

2019 HY results

image description

Outlook 2020

The outlook will be updated upon closing of the planned Ra Pharma acquisition (Q1 2020).

2020 revenue

€ 5.05 - € 5.15 billion 

Recurring EBITDA [Operating profit adjusted for amortisation, depreciation, impairment charges, restructuring expenses and other exceptional income and expenses.] 

28% - 29%

Core earnings per share

€ 4.80 - € 5.20

based on an average of 187 million shares outstanding


Contact UCB IR team or a specific team member:




UCB IR app available on Apple Store

UCB IR app available on Google Play